COVID VACCINE MAKERS BRACE FOR A VARIANT WORSE THAN DELTA
The possible emergence of an ‘escape variant’, a dominant strain of SARS-CoV-2 that evades the fledgling immunity established through vaccines and previous infections is driving vaccine makers to run dress rehearsals. If an escape variant emerges, RNA vaccine makers such as Pfizer and Moderna could probably design and synthesize an initial prototype jab against it in a few days.
Full Access: Nature
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Heart groups release guidelines designed to help clinicians evaluate source and symptoms of chest pain while improving patient outcomes, reducing health care costs. New guidelines designed to help clinicians evaluate the source and symptoms of chest pain while improving patient outcomes and reducing health care costs.
Full Access: Journal of the American College of Cardiology
EFFECT OF EARLY TREATMENT WITH FLUVOXAMINE ON RISK OF EMERGENCY CARE AND HOSPITALISATION AMONG PATIENTS WITH COVID-19: THE TOGETHER RANDOMISED, PLATFORM CLINICAL TRIAL
This placebo-controlled, randomized, adaptive platform trial done among high-risk symptomatic Brazilian adults confirmed positive for SARS-CoV-2 showed that the proportion of patients observed in a COVID-19 emergency setting for more than 6 h or transferred to a tertiary hospital due to COVID-19 was lower for the fluvoxamine (100 mg twice daily for 10 days) group compared with placebo. No significant differences in number of treatment emergent adverse events among patients in the fluvoxamine and placebo groups.
Full Access: The Lancet
A PILL FOR C DIFFICILE WORKS BY INCREASING MICROBIOME DIVERSITY
An oral treatment with freeze-dried human stool can successfully treat Clostridioides difficile infections by increasing the diversity of microorganisms in the colon, hence restoring natural diversity that has been disrupted by antibiotics. Study showed that after 8 weeks, 74.5% of those given the pills had not had a recurrence, compared with 61.5% of those given the placebo. The difference was just barely statistically significant (P = .0488).
Full Access: Medscape
